GSK Velu’s $4B IPO Plan: 4 Businesses Eye Public Markets

Serial healthcare entrepreneur GSK Velu is gearing up to take four of his flagship businesses public, a move anticipated to unlock over $4 billion in value for investors. With combined revenues already exceeding ₹7,000 crore, these listings signal significant growth potential in India’s medical sector over the next three years.

📌 What Happened?

Velu intends to list Trivitron, Neuberg Diagnostics, Maxi Vision, and Kauvery Hospitals on the public markets. These companies represent diverse segments of the healthcare industry, from medical technology to eye care and hospital networks.

The initial public offerings are projected to begin with Neuberg Diagnostics and Maxi Vision, potentially launching in 2027. Kauvery Hospitals is slated to follow, while Trivitron, Velu’s primary medical technology firm, awaits a major acquisition and additional private equity funding before its own listing.

GSK Velu holds substantial stakes across these ventures, including full ownership of Trivitron, roughly two-thirds of Neuberg Diagnostics, and over 60% of Maxi Vision. He also maintains more than 20% ownership in Kauvery Hospitals, alongside a 30% stake in Apollo Dental and Apollo Dialysis.

Trivitron, established in 1997, leads in Indian medical equipment manufacturing with 11 facilities across India and international units. It projects ₹1,000 crore in revenue by FY27, aiming to triple turnover within five years.

Neuberg Diagnostics, launched in October 2017, focuses on advanced diagnostics like genomics. Operating around 250 labs in India, it reported ₹1,600-1,700 crore last year and targets ₹2,000 crore in FY27.

Maxi Vision, an eye care network acquired by Velu in 2010, now manages approximately 70 eye hospitals and 20 clinics, generating about ₹600 crore annually. Kauvery Hospitals, with Velu’s involvement since 2015, expanded to 14 hospitals and nearly 3,000 beds, primarily in Tamil Nadu and Bengaluru.

💰 Why It Matters

This strategic move by Velu highlights the booming private healthcare sector in India, making it a prime area for investment. The listings offer young investors a chance to diversify into a resilient and high-growth industry.

The potential $4 billion value unlock underscores the significant wealth creation opportunities emerging from established, yet rapidly expanding, Indian businesses. This isn’t just about big numbers; it’s about tangible growth that could reshape portfolios.

The staggered IPO timeline allows investors to watch performance and market sentiment before committing. It also signals Velu’s confidence in each company’s individual growth trajectory and market readiness.

👀 What to Watch Next

Keep an eye on the specific filings for Neuberg Diagnostics and Maxi Vision as they approach their anticipated 2027 IPOs. Their performance could set the tone for the subsequent listings.

Monitor Trivitron’s progress regarding its strategic acquisition and private equity funding rounds. These developments will be crucial indicators for its eventual public market debut and future valuation.

The expansion of Kauvery Hospitals, particularly its bed capacity and regional footprint, will be a key metric to track. Growth in this segment reflects the increasing demand for quality healthcare infrastructure across India.